Barriers and facilitators when implementing family involvement for persons with psychotic disorders in community mental health centres - a nested qualitative study.
Barriers
Facilitators
Family interventions
Family involvement
Family psychoeducation
Implementation
Mental health services research
Psychotic disorders
Journal
BMC health services research
ISSN: 1472-6963
Titre abrégé: BMC Health Serv Res
Pays: England
ID NLM: 101088677
Informations de publication
Date de publication:
12 Sep 2022
12 Sep 2022
Historique:
received:
10
02
2022
accepted:
23
08
2022
entrez:
12
9
2022
pubmed:
13
9
2022
medline:
15
9
2022
Statut:
epublish
Résumé
The uptake of family involvement in health care services for patients with psychotic disorders is poor, despite a clear evidence base, socio-economic and moral justifications, policy, and guideline recommendations. To respond to this knowledge-practice gap, we established the cluster randomised controlled trial: Implementation of guidelines on Family Involvement for persons with Psychotic disorders in community mental health centres (IFIP). Nested in the IFIP trial, this sub-study aims to explore what organisational and clinical barriers and facilitators local implementation teams and clinicians experience when implementing family involvement in mental health care for persons with psychotic disorders. We performed 21 semi-structured focus groups, including 75 participants in total. Implementation team members were interviewed at the initial and middle phases of the intervention period, while clinicians who were not in the implementation team were interviewed in the late phase. A purposive sampling approach was used to recruit participants with various engagement in the implementation process. Data were analysed using manifest content analysis. Organisational barriers to involvement included: 1) Lack of shared knowledge, perceptions, and practice 2) Lack of routines 3) Lack of resources and logistics. Clinical barriers included: 4) Patient-related factors 5) Relative-related factors 6) Provider-related factors. Organisational facilitators for involvement included: 1) Whole-ward approach 2) Appointed and dedicated roles 3) Standardisation and routines. Clinical facilitators included: 4) External implementation support 5) Understanding, skills, and self-efficacy among mental health professionals 6) Awareness and attitudes among mental health professionals. Implementing family involvement in health care services for persons with psychotic disorders is possible through a whole-ward and multi-level approach, ensured by organisational- and leadership commitment. Providing training in family psychoeducation to all staff, establishing routines to offer a basic level of family involvement to all patients, and ensuring that clinicians get experience with family involvement, reduce or dissolve core barriers. Having access to external implementation support appears decisive to initiate, promote and evaluate implementation. Our findings also point to future policy, practice and implementation developments to offer adequate treatment and support to all patients with severe mental illness and their families. ClinicalTrials.gov Identifier NCT03869177. Registered 11.03.19.
Sections du résumé
BACKGROUND
BACKGROUND
The uptake of family involvement in health care services for patients with psychotic disorders is poor, despite a clear evidence base, socio-economic and moral justifications, policy, and guideline recommendations. To respond to this knowledge-practice gap, we established the cluster randomised controlled trial: Implementation of guidelines on Family Involvement for persons with Psychotic disorders in community mental health centres (IFIP). Nested in the IFIP trial, this sub-study aims to explore what organisational and clinical barriers and facilitators local implementation teams and clinicians experience when implementing family involvement in mental health care for persons with psychotic disorders.
METHODS
METHODS
We performed 21 semi-structured focus groups, including 75 participants in total. Implementation team members were interviewed at the initial and middle phases of the intervention period, while clinicians who were not in the implementation team were interviewed in the late phase. A purposive sampling approach was used to recruit participants with various engagement in the implementation process. Data were analysed using manifest content analysis.
RESULTS
RESULTS
Organisational barriers to involvement included: 1) Lack of shared knowledge, perceptions, and practice 2) Lack of routines 3) Lack of resources and logistics. Clinical barriers included: 4) Patient-related factors 5) Relative-related factors 6) Provider-related factors. Organisational facilitators for involvement included: 1) Whole-ward approach 2) Appointed and dedicated roles 3) Standardisation and routines. Clinical facilitators included: 4) External implementation support 5) Understanding, skills, and self-efficacy among mental health professionals 6) Awareness and attitudes among mental health professionals.
CONCLUSIONS
CONCLUSIONS
Implementing family involvement in health care services for persons with psychotic disorders is possible through a whole-ward and multi-level approach, ensured by organisational- and leadership commitment. Providing training in family psychoeducation to all staff, establishing routines to offer a basic level of family involvement to all patients, and ensuring that clinicians get experience with family involvement, reduce or dissolve core barriers. Having access to external implementation support appears decisive to initiate, promote and evaluate implementation. Our findings also point to future policy, practice and implementation developments to offer adequate treatment and support to all patients with severe mental illness and their families.
TRIAL REGISTRATION
BACKGROUND
ClinicalTrials.gov Identifier NCT03869177. Registered 11.03.19.
Identifiants
pubmed: 36096844
doi: 10.1186/s12913-022-08489-y
pii: 10.1186/s12913-022-08489-y
pmc: PMC9469513
doi:
Banques de données
ClinicalTrials.gov
['NCT03869177']
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1153Subventions
Organisme : Norges Forskningsråd
ID : 262863
Organisme : Norges Forskningsråd
ID : 262863
Organisme : Norges Forskningsråd
ID : 262863
Organisme : Norges Forskningsråd
ID : 262863
Organisme : Norges Forskningsråd
ID : 262863
Organisme : Norges Forskningsråd
ID : 262863
Organisme : Norges Forskningsråd
ID : 262863
Organisme : Norges Forskningsråd
ID : 262863
Informations de copyright
© 2022. The Author(s).
Références
World Psychiatry. 2011 Oct;10(3):229-36
pubmed: 21991284
Int J Soc Psychiatry. 2015 Feb;61(1):10-6
pubmed: 24869849
Fam Process. 2016 Sep;55(3):460-82
pubmed: 27411376
J Psychiatr Ment Health Nurs. 2005 Aug;12(4):488-94
pubmed: 16011505
Psychiatr Serv. 2001 Jul;52(7):903-10
pubmed: 11433107
Psychiatr Serv. 2013 Mar 1;64(3):257-63
pubmed: 23242515
J Marital Fam Ther. 2012 Jan;38(1):101-21
pubmed: 22283383
Milbank Q. 2001;79(2):281-315
pubmed: 11439467
BMC Health Serv Res. 2017 May 15;17(1):349
pubmed: 28506296
Acad Med. 2014 Sep;89(9):1245-51
pubmed: 24979285
Clin Psychol Rev. 2013 Apr;33(3):372-82
pubmed: 23410719
J Adv Nurs. 2008 Apr;62(1):107-15
pubmed: 18352969
BMC Psychiatry. 2015 Sep 24;15:228
pubmed: 26403843
Aust N Z J Psychiatry. 2016 May;50(5):410-72
pubmed: 27106681
Afr J Emerg Med. 2017 Sep;7(3):93-99
pubmed: 30456117
Early Interv Psychiatry. 2017 Oct;11(5):365-374
pubmed: 28418227
Health Soc Care Community. 2009 Mar;17(2):125-32
pubmed: 18700869
Health Serv Res. 1999 Dec;34(5 Pt 2):1189-208
pubmed: 10591279
Cancer Causes Control. 2018 Mar;29(3):363-369
pubmed: 29417296
Br J Psychiatry. 1997 Nov;171:401-5
pubmed: 9463594
BMJ. 2014 Feb 12;348:g1173
pubmed: 24523363
Early Interv Psychiatry. 2018 Aug;12(4):535-560
pubmed: 29076263
Worldviews Evid Based Nurs. 2019 Oct;16(5):332-334
pubmed: 31603625
J Gen Intern Med. 2010 Jan;25 Suppl 1:32-7
pubmed: 20077149
Ment Health Serv Res. 2000 Jun;2(2):75-87
pubmed: 11256719
Br J Psychiatry. 2015 Apr;206(4):268-74
pubmed: 25833867
Clin Psychol Psychother. 2011 Jan-Feb;18(1):48-59
pubmed: 21110400
BMC Psychiatry. 2021 Jun 2;21(1):285
pubmed: 34078306
Annu Rev Clin Psychol. 2013;9:465-97
pubmed: 23330939
Qual Health Res. 2008 Nov;18(11):1556-65
pubmed: 18849516
Br J Psychiatry. 2007 Feb;190:148-55
pubmed: 17267932
Int J Nurs Stud. 2017 Jan;66:47-59
pubmed: 27987411
J Gen Intern Med. 2006 Feb;21 Suppl 2:S1-8
pubmed: 16637954
J Ment Health. 2014 Aug;23(4):162-5
pubmed: 24433132
BMJ Open. 2014 Oct 03;4(10):e006108
pubmed: 25280809
Psychol Psychother. 2016 Sep;89(3):324-50
pubmed: 26537838
Lancet Psychiatry. 2022 Mar;9(3):211-221
pubmed: 35093198
Nurse Educ Today. 2004 Feb;24(2):105-12
pubmed: 14769454
BMC Health Serv Res. 2020 Oct 9;20(1):934
pubmed: 33036605
BMJ Open. 2017 Sep 27;7(9):e017680
pubmed: 28963308
Milbank Q. 2004;82(4):581-629
pubmed: 15595944
Adm Policy Ment Health. 2015 Sep;42(5):533-44
pubmed: 24193818
Cochrane Database Syst Rev. 2010 Dec 08;(12):CD000088
pubmed: 21154340
Lancet Psychiatry. 2021 Nov;8(11):969-980
pubmed: 34653393
Schizophr Bull. 2001;27(1):73-92
pubmed: 11215551
PLoS One. 2019 May 13;14(5):e0216887
pubmed: 31083693